CSL has received approval from the European Commission (EC) for Andembry (garadacimab) to prevent recurrent attacks of ...

CSL has been given approval by the European Commission for Andembry, the first once-monthly preventive therapy for the ...

The European Commission (EC) has approved CSL’s Andembry (garadacimab) to prevent attacks of hereditary angioedema (HAE) in ...

Global biotechnology leader CSL has announced that the European Commission (EC) has approved ANDEMBRY (garadacimab), the ...

Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced that the European Commission (EC) has approved ...

Korea is expected to spend around 6 trillion won ($4.6 billion) this year on treating diseases related to aging such as ...

RESEARCH TRIANGLE PARK, N.C. - BioCryst Pharmaceuticals , Inc. (NASDAQ:BCRX), a biotechnology company with impressive revenue growth of nearly 30% over the last twelve months, has announced that ...

KalVista Pharmaceuticals, Inc. , today announced the presentation of novel data related to long-term prophylaxis and sebetralstat at the Western Society of Allergy, Asthma & Immunology (WSAAI) 2025 ...

A woman suffering debilitating symptoms is crediting WVU Medicine for giving her her life back after finally receiving a ...

In 2019, mental health disorders were one of the top four leading causes of disease burden in Singapore[2]. The research team thus set out to investigate the role microbes play in anxious behaviour.

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved CSL’s Andembry (garadacimab) to prevent ...

The healthcare industry is set for growth due to advancements in targeted treatments and personalized care and the rapid ...